17,261 trials
Knee Osteoarthritis
Primary: Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline — -3.56; -3.29; -1.00 units on a scale
Chronic Graft-versus-host-disease
Primary: Duration of Response (DOR) — NA; NA months
Atopic Dermatitis
Primary: Part 1 (Phase I) Primary: Maximum Tolerable Dose — 29.2 Grams of IP per application
Neurofibromatosis Type 1 · Plexiform Neurofibroma
Primary: Change From Baseline Target Tumor Volume at 12 Months — 27; 17 Participants
Acute Kidney Injury Due to Sepsis
Primary: Maximum Serum Concentration (Cmax) of TIN816 — 40.8 ug/mL
Retinitis Pigmentosa
Primary: Change in Humphrey Visual Fields - Total Sensitivity — 1.4; 16.8; -164.8; -66.7 dB
Metastatic Colorectal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose (RP2D) of MEN1611 in Combination With Cetuximab — 48 mg
Pediatric Cancer · CNS Tumor, Childhood · Skin Inflammation
Primary: Rate of Cutaneous Reaction — 7 Participants
Neuroendocrine Tumors
Primary: To Determine the Biodistribution of [18F] Following Single I.V Administration of [18F]-FET-βAG-TOCA Injection in Patients With a Histological Diagnosis of NET. — 0.002…
Plasma Cell Myeloma
Primary: Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. — 0; 0; 0; 0 Participants
Amyotrophic Lateral Sclerosis · Muscle Cramp
Primary: Visual Analog Scale (MCS-VAS) Score — 2.07; 1.7 score on a scale
Alcohol Use Disorder · Inflammatory Response · Craving
Primary: Cue-induced Craving — 4.5004; 7.9081; 4.5004; 5.6178 score on a scale — p=0.036
Sjögren's Syndrome
Primary: Population 1: Change From Baseline in ESSDAI at Day 169 — -4.1; -6.3 Score on scale
Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
Primary: Number of Instances of Potentially Unattended Psilocybin-related Distress During Psilocybin Sessions. — 0 Events
Neuromyelitis Optica
Primary: Change in Pain Score on the Numerical Rating Score (NRS) — 2.2; 1.3 units on a scale